Home - Products - Angiogenesis - JAK - JKA3 inhibitor 31

JKA3 inhibitor 31

CAS No. 1637749-82-6

JKA3 inhibitor 31( —— )

Catalog No. M12470 CAS No. 1637749-82-6

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

JKA3 inhibitor 31
Note

Research use only, not for human use.
Brief Description

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM.
Description

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases; also inhibits BLK, ERB-B4 and ITK with IC50 of 22 nM, 44 nM and 221 nM, respectively.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Angiogenesis
Target

JAK
Recptor

JAK
Research Area

——
Indication

——

Chemical Information

CAS Number

1637749-82-6
Formula Weight

288.31
Molecular Formula

C17H12N4O
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

3-(3-(1H-indazol-4-yl)phenyl)-2-cyanoacrylamide

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. London N, et al. Nat Chem Biol. 2014 Dec;10(12):1066-72. 2. Clark JD, et al. J Med Chem. 2014 Jun 26;57(12):5023-38.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

BT-11

BT-11 is an orally available LANCL2 binding compound. It is used in the therapy of inflammatory bowel disease.
Pumecitinib

Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.
AZD-1480

A potent, selective, ATP competitive JAK2 inhibitor with Ki of 0.26 nM.

Sign In Join Free